| Literature DB >> 25407698 |
Juan Serrano-Ferrer, Guillaume Walther, Edward Crendal, Agnès Vinet, Frédéric Dutheil, Geraldine Naughton, Bruno Lesourd, Robert Chapier, Daniel Courteix, Philippe Obert.
Abstract
BACKGROUND: Growing evidence demonstrates subtle left ventricular myocardial dysfunction in patients with metabolic syndrome (MetS), with central obesity, glucose intolerance and inflammation emerging as important contributors. Whether these results can be translated to the right ventricle (RV) is not yet fully elucidated. Furthermore, although lifestyle intervention favorably impacts MetS components and inflammatory biomarkers, its effect on RV myocardial function remains unknown today.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25407698 PMCID: PMC4149206 DOI: 10.1186/s12933-014-0116-9
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Figure 1Representative curves for RV global longitudinal strain (%): one control (top left) and one MetS patient (top right), one MetS patient before (bottom left) and after (bottom right) the 3-month life style intervention program.
General characteristics and clinical data
| Age (y) | 58.0 ± 4.2 | 59.6 ± 4.6 | 59.4 ± 4.4 | |
| Sex (female,%) | 20 (50.0) | 20 (51.2) | 17 (51.5) | |
| MetS criteria | | | | |
| Increased blood pressure (n,%) | 8 (20.0) | 31 (79.4)*** | 27 (81.8) | 21 (63.6)#*** |
| Reduced HDL (n,%) | 6 (15.0) | 29 (74.3)*** | 23 (69.7) | 22 (66.6)*** |
| Increased fasting glucose (n,%) | 0 (0.0) | 10 (25.6)** | 7 (21.2) | 2 (6.1) |
| Increased TG (n,%) | 4 (1.0) | 32 (82.0)*** | 27 (81.8) | 22 (66.6)*** |
| Height (cm) | 169.2 ± 8.4 | 165.6 ± 8.2 | 166.1 ± 8.7 | |
| Body weight (kg) | 68.1 ± 12.4 | 85.9 ± 9.9*** | 86.0 ± 10.2 | 79.5 ± 9.1###*** |
| BMI (kg.m−2) | 23.9 ± 3.1 | 32.8 ± 3.5*** | 31.9 ± 3.5 | 28.8 ± 3.2###*** |
| Waist circumference (cm) | 81.9 ± 8.0 | 99.3 ± 7.9*** | 98.4 ± 7.6 | 91.0 ± 6.8###*** |
| Central Fat (kg) | 1.2 ± 0.5 | 3.0 ± 0.6*** | 3.0 ± 0.7 | 2.3 ± 0.6###*** |
| Systolic blood pressure (mmHg) | 116 ± 11 | 130 ± 15* | 132 ± 14 | 120 ± 15#*** |
| Diastolic blood pressure (mmHg) | 73 ± 8 | 77 ± 10 | 76 ± 9 | 70 ± 9*** |
| Heart rate (bpm) | 61 ± 4 | 71 ± 10*** | 69 ± 10 | 65 ± 12##** |
| LDL-cholesterol (mmol.l−1) | 3.6 ± 0.7 | 3.5 ± 0.8 | 3.5 ± 0.9 | 3.1 ± 0.8##** |
| HDL- cholesterol (mmol.l−1) | 1.6 ± 0.5 | 1.2 ± 0.3*** | 1.2 ± 0.3 | 1.3 ± 0.4** |
| TG (mmol.l−1) | 1.1 ± 0.4 | 2.0 ± 1.0*** | 1.9 ± 1.0 | 1.5 ± 0.6###** |
| Fasting glucose (mmol.l−1) | 4.2 ± 0.5 | 5.0 ± 0.9*** | 4.9 ± .7 | 4.1 ± 0.6### |
| Fasting insulin (mIU.l−1) | 30.2 ± 15.1 | 40.5 ± 13.9** | 39.7 ± 14.3 | 35.0 ± 12.3# |
| HbA1C (%) | 5.4 ± 0.4 | 5.9 ± 0.4*** | 5.9 ± 0.3 | 5.7 ± 0.3###** |
| HOMA-IR | 2.2 ± 1.3 | 3.6 ± 1.4*** | 3.5 ± 1.3 | 2.6 ± 1.1### |
| NT-proBNP (pg.ml−1) | 22.4 ± 37.7 | 33.6 ± 51.3 | 34.3 ± 52.5 | 44.7 ± 79.3 |
| IL6 (pg.ml−1) | 1.2 ± 1.1 | 3.0 ± 3.5* | 2.7 ± 2.8 | 1.9 ± 2.7 |
| PAI-1 active (pg.ml−1) | 7.7 ± 4.9 | 14.0 ± 7.1*** | 12.7 ± 6.4 | 9.5 ± 4.1##* |
| Adiponectin (μg.ml−1) | 32.8 ± 22.0 | 17.3 ± 12.0*** | 17.2 ± 13.0 | 15.8 ± 10.6*** |
| hsCRP (mg.l−1) | 1.72 ± 2.77 | 4.03 ± 3.37*** | 4.12 ± 3.37 | 3.08 ± 3.89# |
| TNF-α (pg.ml−1) | 3.5 ± 3.0 | 11.7 ± 8.0*** | 12.0 ± 8.3 | 5.1 ± 4.1### |
| Routine medication: | | | | |
| Arterial hypertension (n,%) | 0 (0.0) | 27 (67.5)*** | 26 (78.8) | 22 (66.7)*** |
| ACE-I/ARBs (n,%) | 0 (0.0) | 20 (51.3)*** | 16 (48.4) | 15 (45.5)*** |
| Calcium antagonist (n,%) | 0 (0.0) | 3 (7.5) | 3 (9.1) | 3 (9.1) |
| Beta-blockers (n,%) | 0 (0.0) | 6 (15.0)* | 5 (15.1) | 4 (12.1)* |
| Diuretics (n,%) | 0 (0.0) | 11 (27.5)*** | 7 (21.2) | 7 (21.2)* |
| Lipid lowering agents (n,%) | 0 (0.0) | 21 (52.5)*** | 16 (48.4) | 15 (45.5)*** |
BMI: body mass index, LDL: low-density lipoprotein, HDL: high-density lipoprotein. TG: triglycerides, HbA1C: glycated hemoglobin, HOMA-IR: homeostatic model assessment of insulin resistance, NT-proBNP: N-terminal pro-B-type natriuretic peptide, IL6: interleukin-6, PAI-1 active: plasminogen activator inhibitor-1, hsCRP: high sensitivity C-reactive protein, TNF-α: Tumor necrosis factor α, ACE-I/ARBs: angiotensin receptor blockers and the angiotensin converting enzyme inhibitors. Significantly different from controls: *P < 0.05, **P < 0.01, ***P < 0.001. Significantly different from baseline in MetS: # P < 0.05, ## P < 0.01, ### P < 0.001.
Left ventricle conventional echocardiography and tissue Doppler data
| LVED diameter (mm) | 47.6 ± 4.9 | 48.9 ± 4.5 | 49.1 ± 4.6 | 49.1 ± 4.7 |
| LVES diameter (mm) | 28.9 ± 4.7 | 28.9 ± 4.4 | 28.9 ± 4.3 | 29.2 ± 3.7 |
| Posterior wall thickness (mm) | 9.9 ± 1.1 | 11.5 ± 1.6*** | 11.4 ± 1.4 | 10.9 ± 0.8*** |
| IV septum thickness (mm) | 9.9 ± 1.4 | 11.2 ± 1.5*** | 11.1 ± 1.3 | 10.8 ± 0.9** |
| LV mass indexed (g.m-2.7) | 48.1 ± 11.9 | 66.1 ± 13.5*** | 63.7 ± 14.3 | 61.0 ± 10.9*** |
| LVEF (%) | 64.1 ± 5.3 | 61.0 ± 4.1** | 61.0 ± 4.1 | 63.0 ± 3.1# |
| | | | | |
| Mitral E velocity (cm.s−1) | 66.0 ± 12.2 | 64.4 ± 14.4 | 66.0 ± 11.9 | 64.5 ± 13.0 |
| Mitral A velocity (cm.s−1) | 50.4 ± 12.2 | 60.9 ± 15.0** | 61.4 ± 15.6 | 57.7 ± 12.4* |
| Mitral E/A | 1.3 ± 0.3 | 1.0 ± 0.2*** | 1.1 ± 0.2 | 1.1 ± 0.2* |
| | | | | |
| Em (cm.s−1) | 10.5 ± 2.0 | 9.6 ± 1.9* | 9.6 ± 1.9 | 9.2 ± 1.0* |
| E/Em | 5.9 ± 1.5 | 6.1 ± 1.6 | 6.1 ± 1.5 | 5.7 ± 0.9 |
LVED: Left ventricular end-diastolic, LVES: Left ventricular end-systolic, IV: inter-ventricular, LV: Left ventricular, EF: ejection fraction, Em: peak early diastolic velocity of the mitral annulus. Significantly different from controls: *P < 0.05, **P < 0.01, ***P < 0.001. Significantly different from baseline in MetS: # P < 0.05.
Right ventricle conventional echocardiography and tissue Doppler data
| RA area (cm2) | 12.9 ± 2.0 | 13.0 ± 2.4 | 12.5 ± 1.9 | 12.7 ± 1.7 |
| RVED diameter (mm) | 38.8 ± 5.0 | 40.5 ± 5.7 | 39.0 ± 4.4 | 40.7 ± 4.5# |
| RV FS (%) | 46 ± 5 | 44 ± 5 | 43 ± 5 | 44 ± 4 |
| TAPSE (mm) | 24.5 ± 2.4 | 22.5 ± 2.5*** | 22.4 ± 2.2 | 22.8 ± 2.1** |
| | | | | |
| Tricuspid E velocity (cm.s−1) | 45.1 ± 7.4 | 46.1 ± 8.0 | 46.4 ± 8.0 | 46.6 ± 8.3 |
| Tricuspid A velocity (cm.s−1) | 29.2 ± 5.9 | 33.1 ± 7.5* | 33.0 ± 8.0 | 29.2 ± 5.1# |
| Tricuspid E/A | 1.6 ± 0.3 | 1.4 ± 0.3* | 1.4 ± 0.31 | 1.6 ± 0.40## |
| Pulmonary acceleration time (ms) | 157 ± 28 | 151 ± 30 | 150 ± 30 | 154 ± 20 |
| Estimated mean PA pressure (mmHg) | 8.4 ± 12.8 | 10.8 ± 13.6 | 9.5 ± 12.7 | 8.7 ± 11.2 |
| | | | | |
| Stri (cm.s−1) | 13.5 ± 2.3 | 12.6 ± 2.0* | 12.2 ± 2.0 | 11.9 ± 1.6** |
| Etri (cm.s−1) | 12.6 ± 2.3 | 11.3 ± 2.3* | 11.6 ± 2.2 | 11.0 ± 2.3* |
| Atri (cm.s−1) | 14.4 ± 2.3 | 14.2 ± 2.4 | 14.1 ± 2.6 | 13.3 ± 3.0* |
| Etri/Atri | 0.87 ± 0.2 | 0.82 ± 0.2 | 0.85 ± 0.2 | 0.88 ± 0.2 |
| Tricuspid E/Etri | 3.7 ± 0.8 | 4.2 ± 1.1* | 4.1 ± 1.0 | 4.3 ± 1.2* |
| IVRT (ms) | 16.3 ± 15.9 | 41.1 ± 26.0*** | 39.6 ± 23.1 | 33.8 ± 21.9*** |
RA: right atrium, RVED: right ventricular end-diastolic, RV FS: RV fractional shortening, TAPSE: tricuspid annular plane systolic excursion, PA: pulmonary artery, Stri: peak systolic velocity of the tricuspid annulus, Etri: peak early diastolic velocity of the triscupid annulus, Atri: peak late diastolic velocity of the tricuspid annulus, IVRT: isovolumic relaxation time. Significantly different from controls: *P < 0.05, **P < 0.01, ***P < 0.001. Significantly different from baseline in MetS: # P < 0.05, ## P < 0.01.
Right ventricle free wall longitudinal strains and strain-rates
| RV strain (%) | | | | |
| RV GLS | −25.7 ± 4.9 | −21.4 ± 4.5*** | −21.8 ± 3.8 | −24.3 ± 4.0## |
| Basal segment | −27.1 ± 7.1 | −23.4 ± 5.1* | −23.7 ± 4.7 | −24.7 ± 7.0 |
| Mid segment | −25.4 ± 5.4 | −20.9 ± 5.0*** | −21.1 ± 4.7 | −23.6 ± 4.2# |
| Apical segment | −24.7 ± 6.1 | −19.7 ± 6.0*** | −20.1 ± 5.8 | −23.7 ± 5.4## |
| RV GLS TTP (ms) | 94 ± 6 | 92 ± 10 | 93 ± 10 | 93 ± 8 |
| RV global systolic SR (.s−1) | −1.8 ± 0.4 | −1.2 ± 0.4*** | −1.2 ± 0.4 | −1.5 ± 0.4## |
| RV global systolic SR TTP (ms) | 51 ± 6 | 50 ± 9 | 48 ± 9 | 50. ± 10 |
| RV global diastolic SR (.s−1) | 1.7 ± 0.5 | 1.3 ± 0.3** | 1.3 ± 0.3 | 1.6 ± 0.4## |
| RV global diastolic SR TTP (ms) | 123 ± 10 | 121 ± 16 | 122 ± 16 | 118 ± 14 |
GLS: global longitudinal strain calculated from the mean of the basal, mid and apical segments of the right ventricle free wall, RV: right ventricular, SR: strain rate, TTP: time to peak. Significantly different from controls: *P < 0.05, **P < 0.01, ***P < 0.001. Significantly different from baseline in MetS: # P < 0.05, ## P < 0.01.
Relationship between RV free wall global strain and clinical, biological and echocardiographic data
| | ||
|---|---|---|
| Age (Years) | 0.15 | ns |
| Systolic blood pressure (mmHg) | 0.12 | ns |
| Diastolic blood pressure (mmHg) | 0.14 | ns |
| Central fat | 0.32 | ** |
| Waist circumference | 0.45 | *** |
| BMI | 0.39 | *** |
| HDL | −0.39 | *** |
| LDL | −0.05 | ns |
| Triglycerides | 0.12 | ns |
| HbA1C | 0.36 | ** |
| Fasting glucose | 0.35 | ** |
| HOMA-IR | 0.22 | * |
| TNF-α | 0.31 | * |
| PAI-1 active | 0.52 | *** |
| IL-6 | 0.30 | ** |
| Adiponectin | −0.53 | *** |
| Left ventricular mass indexed | 0.43 | *** |
| Etri | −0.37 | ** |
| Stri | −0.26 | * |
| E/Etri | 0.39 | ** |
BMI: Body mass index, LDL: low-density lipoprotein, HDL: high-density lipoprotein, HbA1C: glycated hemoglobin, HOMA-IR: homeostatic model assessment of insulin resistance, TNF-α: Tumor necrosis factor α, PAI-1 active: plasminogen activator inhibitor-1, IL6: interleukin-6, Etri: peak early diastolic velocity of the tricuspid annulus, Stri: peak systolic velocity of the tricuspid annulus. Significant differences categorized as: *P < 0.05, **P < 0.01, ***P < 0.001. ns: non-significant.